Journal
DRUG DISCOVERY TODAY
Volume 28, Issue 3, Pages -Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.drudis.2023.103490
Keywords
Mycobacterium tuberculosis; Transcription termination; Rho inhibition; Drug discovery
Categories
Ask authors/readers for more resources
This review provides an overview of the essentiality of Rho in Mycobacterium tuberculosis, making it an attractive drug target for inhibitor discovery.
Mycobacterial infections, including multidrug and extreme drug-resistant (MDR and XDR) infections, are a severe challenge and create a virtual antibiotic-deficient era. Bacterial transcription is an established antimicrobial drug target. In mycobacteria, efficient transcription termination relies on the ATP-dependent RNA helicase factor Rho. Rho factor is essential for Mycobacterium tuberculosis (Mtb) survival, and is a valid antibacterial drug target with no homolog in eukaryotes. Rho maintains genomic stability and virulence and prevents pervasive transcription in Mtb. In this review, we provide an overview of the essentiality of Rho in Mtb, which makes it an attractive drug target for inhibitor discovery.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available